Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Mirati Therapeutics, Inc. is a targeted oncology company developing a pipeline of therapeutics for precisely defined patient populations. The Mirati team is using a blueprint proven by their prior work for developing potential breakthrough therapies with accelerated development paths.
Website: mirati.com



Growth: Bad revenue growth rate -93.1%, there is slowdown compared to average historical growth rates 74.5%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -731.7%. On average the margin is decreasing steadily. Gross margin is high, +100.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.24 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -2.1% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 111.2% higher than minimum and 69.2% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -32.8x by EV / Sales multiple

Key Financials (Download financials)

Ticker: MRTX
Share price, USD:  (0.0%)58.7
year average price 49.01  


year start price 42.63 2023-04-22

min close price 27.80 2023-08-08

max close price 62.38 2023-10-05

current price 58.70 2024-04-20
Common stocks: 56 219 000

Dividend Yield:  0.0%
Last revenue growth (y/y):  > 200.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  74.5%
Historical growth of EBITDA:  0.0%
EV / Sales: 26.1x
Margin (EBITDA LTM / Revenue): -731.7%
Fundamental value created in LTM:
Market Cap ($m): 3 300
Net Debt ($m): -1 157
EV (Enterprise Value): 2 143
Price to Book: 3.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-05Finbold

How this insider trader nailed every single stock trade

2024-01-11Zacks Investment Research

Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC

2023-12-06Zacks Investment Research

Mirati (MRTX) Up 1.1% Since Last Earnings Report: Can It Continue?

2023-11-10Reuters

Mirati's lung cancer drug gets EU's regulatory backing

2023-11-07Zacks Investment Research

Mirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations

2023-10-09Schaeffers Research

Analysts Target Biotech Name on Buyout Buzz

2023-10-08Reuters

Bristol-Myers Squibb to acquire Mirati in a $4.8 billion deal

2023-10-06Zacks Investment Research

Mirati (MRTX) Surges 45% as Sanofi Reportedly Eyes Buyout

2023-09-22Zacks Investment Research

Mirati (MRTX) Soars 12.3%: Is Further Upside Left in the Stock?

2023-08-09Zacks Investment Research

Mirati (MRTX) Q2 Earnings Beat, Stock Up on Solid Krazati Sales
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol MRTX MRTX MRTX MRTX MRTX
reportedCurrency USD USD USD USD USD
cik 2M 2M 2M 2M 2M
fillingDate 2023-11-06 2023-08-08 2023-05-09 2023-02-28 2022-11-08
acceptedDate 2023-11-06 07:08:36 2023-08-08 16:02:56 2023-05-09 16:22:07 2023-02-28 16:26:14 2022-11-08 16:32:24
calendarYear 2023.000 2023.000 2023.000 2022.000 2022.000
period Q3 Q2 Q1 Q4 Q3
revenue 16M 14M 7M 934 000 5M
costOfRevenue 1M 1M 817 000 600 000 0
grossProfit 15M 12M 6M 334 000 5M
grossProfitRatio 0.913 0.906 0.886 0.358 1.000
researchAndDevelopmentExpenses 115M 124M 127M 141M 131M
generalAndAdministrativeExpenses 0 0 0 169M 61M
sellingAndMarketingExpenses 0 0 0 -98M 0
sellingGeneralAndAdministrativeExpenses 72M 75M 73M 71M 61M
otherExpenses 259 000 10M 9M 10M 0
operatingExpenses 187M 200M 200M 212M 192M
costAndExpenses 188M 201M 201M 213M 192M
interestIncome 0 0 0 0 0
interestExpense 0 0 -3M -6M -13M
depreciationAndAmortization 1M 1M 1M 891 000 716 000
ebitda -172M -186M -194M -212M -186M
ebitdaratio -10.491 -13.598 -27.044 -226.684 -34.198
operatingIncome -172M -187M -194M -212M -186M
operatingIncomeRatio -10.491 -13.679 -27.044 -226.684 -34.329
totalOtherIncomeExpensesNet 10M 10M 9M 10M 13M
incomeBeforeTax -162M -177M -185M -202M -173M
incomeBeforeTaxRatio -9.872 -12.923 -25.755 -216.511 -31.911
incomeTaxExpense -1M 0 -9M 254 000 254 000
netIncome -162M -177M -175M -202M -174M
netIncomeRatio -9.872 -12.923 -24.466 -216.783 -31.957
eps -2.490 -3.040 -3.020 -3.510 -3.090
epsdiluted -2.490 -3.040 -3.020 -3.510 -3.090
weightedAverageShsOut 65M 58M 58M 58M 56M
weightedAverageShsOutDil 65M 58M 58M 58M 56M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Balance Sheet Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol MRTX MRTX MRTX MRTX MRTX
reportedCurrency USD USD USD USD USD
cik 2M 2M 2M 2M 2M
fillingDate 2023-11-06 2023-08-08 2023-05-09 2023-02-28 2022-11-08
acceptedDate 2023-11-06 07:08:36 2023-08-08 16:02:56 2023-05-09 16:22:07 2023-02-28 16:26:14 2022-11-08 16:32:24
calendarYear 2023.000 2023.000 2023.000 2022.000 2022.000
period Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 259M 130M 242M 235M 299M
shortTermInvestments 718M 650M 660M 849M 902M
cashAndShortTermInvestments 976M 779M 902M 1 084M 1 201M
netReceivables 20M 16M 6M 865 000 2M
inventory 20M 9M 4M 3M 0
otherCurrentAssets 25M 20M 27M 21M 23M
totalCurrentAssets 1 036M 819M 939M 1 109M 1 226M
propertyPlantEquipmentNet 51M 52M 53M 54M 54M
goodwill 0 0 0 0 0
intangibleAssets 14M 14M 15M 15M 0
goodwillAndIntangibleAssets 14M 14M 15M 15M 0
longTermInvestments 4M 5M 3M 3M 2M
taxAssets 24M 24M 0 0 0
otherNonCurrentAssets 620 000 620 000 23M 22M 21M
totalNonCurrentAssets 94M 96M 94M 94M 77M
otherAssets 0 0 0 0 0
totalAssets 1 130M 915M 1 034M 1 203M 1 303M
accountPayables 38M 33M 22M 39M 19M
shortTermDebt 8M 8M 8M 8M 7M
taxPayables 0 0 0 0 0
deferredRevenue -8M -8M 0 0 0
otherCurrentLiabilities 99M 107M 94M 113M 100M
totalCurrentLiabilities 137M 140M 125M 159M 127M
longTermDebt 42M 43M 43M 44M 44M
deferredRevenueNonCurrent 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0
otherNonCurrentLiabilities 4M 3M 3M 3M 20M
totalNonCurrentLiabilities 46M 46M 47M 47M 47M
otherLiabilities 0 0 0 0 0
capitalLeaseObligations 50M 51M 43M 44M 51M
totalLiabilities 183M 186M 171M 206M 174M
preferredStock 0 0 0 0 0
commonStock 70 000 58 000 58 000 58 000 58 000
retainedEarnings -2 976M -2 814M -2 637M -2 453M -2 250M
accumulatedOtherComprehensiveIncomeLoss -2M -2M -2M -4M -6M
othertotalStockholdersEquity 3 924M 3 545M 3 502M 3 453M 3 386M
totalStockholdersEquity 946M 729M 863M 997M 1 129M
totalEquity 946M 729M 863M 997M 1 129M
totalLiabilitiesAndStockholdersEquity 1 130M 915M 1 034M 1 203M 1 303M
minorityInterest 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 130M 915M 1 034M 1 203M 1 303M
totalInvestments 718M 650M 660M 849M 904M
totalDebt 50M 51M 43M 52M 51M
netDebt -208M -79M -199M -184M -248M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Cash Flow Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol MRTX MRTX MRTX MRTX MRTX
reportedCurrency USD USD USD USD USD
cik 2M 2M 2M 2M 2M
fillingDate 2023-11-06 2023-08-08 2023-05-09 2023-02-28 2022-11-08
acceptedDate 2023-11-06 07:08:36 2023-08-08 16:02:56 2023-05-09 16:22:07 2023-02-28 16:26:14 2022-11-08 16:32:24
calendarYear 2023.000 2023.000 2023.000 2022.000 2022.000
period Q3 Q2 Q1 Q4 Q3
netIncome -162M -177M -185M -202M -174M
depreciationAndAmortization 1M 1M 1M 891 000 716 000
deferredIncomeTax -122M -144M 0 0 0
stockBasedCompensation 45M 39M 47M 62M 43M
changeInWorkingCapital -23M 12M -49M 17M 2M
accountsReceivables -4M -4M -5M -865 000 0
inventory -12M -5M -829 000 -3M 0
accountsPayables 0 0 -35M -5M 0
otherWorkingCapital -7M 21M 41M 26M 0
otherNonCashItems 117M 138M -5M -6M -10M
netCashProvidedByOperatingActivities -144M -131M -190M -129M -138M
investmentsInPropertyPlantAndEquipment -36 000 -722 000 -269 000 -810 000 -1M
acquisitionsNet 62M -16M 0 0 0
purchasesOfInvestments -342M -237M -127M -237M -378M
salesMaturitiesOfInvestments 280M 253M 322M 297M 393M
otherInvestingActivites -62M 16M 0 0 0
netCashUsedForInvestingActivites -62M 16M 195M 59M 14M
debtRepayment 0 0 0 0 0
commonStockIssued 329M 3M 2M 155M 0
commonStockRepurchased 0 0 0 0 0
dividendsPaid 0 0 0 0 0
otherFinancingActivites 6M -3M 0 -149M 157M
netCashUsedProvidedByFinancingActivities 335M 4M 2M 6M 157M
effectOfForexChangesOnCash 59 000 -34 000 -31 000 0 0
netChangeInCash 129M -112M 7M -64M 33M
cashAtEndOfPeriod 259M 130M 243M 236M 299M
cashAtBeginningOfPeriod 130M 243M 236M 299M 266M
operatingCashFlow -144M -131M -190M -129M -138M
capitalExpenditure -36 000 -722 000 -269 000 -810 000 -1M
freeCashFlow -144M -132M -190M -130M -139M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Earning call transcript

2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-09 ET (fiscal 2023 q1)
2022 q4
2023-02-28 ET (fiscal 2022 q4)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-03 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-01-10 13:00 ET
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
2023-11-10 12:30 ET
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
2023-11-06 13:00 ET
Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
2023-11-03 21:19 ET
Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
2023-10-20 13:01 ET
MRTX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Mirati Therapeutics, Inc. to Bristol Myers Squibb
2023-10-17 20:00 ET
Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)
2023-10-17 13:00 ET
Bristol Myers Squibb Joins Big Pharma’s Race to Dominate Oncology
2023-10-08 21:16 ET
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
2023-09-27 20:30 ET
Mirati To Present Updated Clinical Data at ESMO Congress 2023
2023-09-10 02:35 ET
Mirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung Cancer
2023-09-05 20:01 ET
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2023-08-29 20:00 ET
Mirati Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-23 20:00 ET
Mirati Therapeutics Announces Departure of Chief Financial Officer Laurie Stelzer
2023-08-21 20:00 ET
Mirati To Present Pooled Clinical Data from Adagrasib's KRYSTAL-1 Study Demonstrating Overall Survival Results at Two-Years of Follow-Up at 2023 World Conference on Lung Cancer
2023-08-11 20:00 ET
Mirati Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
2023-08-09 20:00 ET
Cancer Discovery Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers through Novel Approach to MTA-Cooperative PRMT5 Inhibition
2023-08-09 04:31 ET
Mirati Therapeutics Announces Pricing of Upsized Public Offering
2023-08-08 20:02 ET
Mirati Therapeutics Announces Proposed Public Offering
2023-08-08 20:01 ET
Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
2023-08-08 20:00 ET
Mirati Therapeutics Announces Departure of Chief Executive Officer David Meek
2023-08-03 20:01 ET
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2023-07-25 20:30 ET
Mirati Therapeutics® to Report Second Quarter 2023 Financial Results and Recent Corporate Updates on August 8, 2023
2023-07-21 11:56 ET
Mirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRAS G12C Mutation
2023-06-23 20:00 ET
Mirati Therapeutics Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent Director
2023-06-20 12:00 ET
Journal of Clinical Oncology Publishes Clinical Results of Adagrasib as a Targeted Treatment for KRASG12C-Mutated NSCLC with Untreated Central Nervous System (CNS) Metastases
2023-06-01 20:30 ET
Mirati Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023
2023-05-30 20:00 ET
Mirati To Encore Compelling Clinical Data Demonstrating Adagrasib's Potential as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors at 2023 ASCO Annual Meeting
2023-05-24 20:01 ET
Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO®
2023-05-09 20:01 ET
Mirati Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Updates
2023-05-08 12:30 ET
Mirati Therapeutics and Sarah Cannon Research Institute Announce Strategic, Community Site Focused Partnership to Increase Diversity in Oncology Clinical Studies
2023-05-05 20:00 ET
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2023-04-27 20:30 ET
Mirati Therapeutics to Participate at the Bank of America Securities 2023 Health Care Conference
2023-04-26 20:34 ET
Journal of Clinical Oncology Publishes Rapid Communication Featuring Updated Clinical Data for Adagrasib as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors
2023-04-25 20:30 ET
Mirati Therapeutics® to Report First Quarter 2023 Financial Results and Recent Corporate Updates on May 9, 2023
2023-04-03 20:00 ET
Mirati To Present Research at the AACR Annual Congress for Two Potentially First-in-Class Clinical Stage Programs
2023-03-06 21:30 ET
Mirati Therapeutics to Participate at the Barclays Global Healthcare Conference
2023-02-28 21:01 ET
Mirati Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates
2023-02-21 21:30 ET
Mirati Therapeutics to Participate at the 43rd Annual Cowen Health Care Conference
2023-02-14 21:30 ET
Mirati Therapeutics to Report Fourth Quarter and Full Year Financial Results for 2022 and Recent Corporate Updates on February 28, 2023
2023-02-03 21:31 ET
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2023-02-01 21:30 ET
Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences
2023-01-19 22:00 ET
Mirati Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral KRASG12D Selective Inhibitor, MRTX1133
2023-01-06 21:00 ET
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2022-12-22 21:30 ET
Mirati Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-21 22:00 ET
Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer
2022-12-13 21:00 ET
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2022-12-13 10:00 ET
QIAGEN receives FDA approval for companion diagnostic to Mirati Therapeutics’ KRAZATI in non-small cell lung cancer
2022-12-12 23:42 ET
Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
2022-12-05 23:05 ET
Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
2022-12-02 13:00 ET
Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study
2022-11-28 13:00 ET
Mirati Therapeutics to Present Late-Breaking Combination Results and Host Virtual Investor Relations Event at ESMO IO
2022-11-08 21:10 ET
Mirati Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Updates
2022-11-08 21:05 ET
Mirati Therapeutics Appoints Alan Sandler, M.D., as Executive Vice President and Chief Medical Officer, Shares Update to Executive Leadership Team
2022-11-07 13:15 ET
Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors
2022-11-02 20:15 ET
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2022-10-25 20:30 ET
Mirati Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Updates
2022-10-12 12:00 ET
Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C] Mutation
2022-10-05 20:30 ET
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2022-09-22 20:30 ET
Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences
2022-09-07 22:05 ET
Mirati Therapeutics Presents Late-Breaking Adagrasib Monotherapy and Combination Results in Advanced Colorectal Cancer
2022-09-02 22:07 ET
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2022-08-31 20:30 ET
Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences
2022-08-04 20:30 ET
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2022-08-03 20:01 ET
Mirati Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Updates
2022-07-20 20:30 ET
Mirati Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Updates
2022-06-06 12:00 ET
New Late-Breaking Data on Investigational Adagrasib Show Regression of Central Nervous System (CNS) Metastases in Patients with KRASG12C-mutated Non-Small Cell Lung Cancer (NSCLC) with Active, Untreated CNS Metastases
2022-05-26 21:00 ET
Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer
2022-05-25 20:30 ET
Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences
2022-05-19 20:30 ET
Mirati Therapeutics Submits Marketing Authorization Application to the European Medicines Agency for Investigational Adagrasib as a Treatment for Previously-Treated KRASG12C-mutated Non-Small Cell Lung Cancer
2022-05-16 20:30 ET
Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer
2022-05-04 20:01 ET
Mirati Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Updates
2022-04-27 20:30 ET
Mirati Therapeutics to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib
2022-04-20 20:30 ET
Mirati Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Updates
2022-03-02 21:33 ET
Mirati Therapeutics to Participate in the 42nd Annual Cowen Healthcare Conference
2022-02-28 21:01 ET
Mirati Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates
2022-02-15 21:15 ET
U.S. Food and Drug Administration (FDA) Accepts Mirati Therapeutics' New Drug Application for Adagrasib as Treatment of Previously Treated KRASG12C-Mutated Non-Small Cell Lung Cancer
2022-02-14 12:30 ET
Mirati Therapeutics to Report Fourth Quarter and Full Year Financial Results for 2021 and Recent Corporate Updates on February 28, 2022
2022-02-02 21:30 ET
Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences
2022-01-21 15:00 ET
Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib in Patients with KRASG12C-Mutated Gastrointestinal Cancers
2022-01-04 21:30 ET
Mirati Therapeutics to Present at the J.P. Morgan 40th Annual Virtual Healthcare Conference
2021-11-23 21:30 ET
Mirati Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference
2021-11-22 12:30 ET
Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer
2021-11-22 12:30 ET
Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer
2021-11-17 12:30 ET
Mirati Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration of MRTX1719 to Treat MTAP-Deleted Cancers
2021-11-11 02:11 ET
Mirati Therapeutics Announces Pricing of Public Offering of Common Stock
2021-11-09 21:23 ET
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
2021-11-09 14:00 ET
Mirati Therapeutics to Participate in the Stifel 2021 Virtual Healthcare Conference
2021-11-08 21:01 ET
Mirati Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Updates
2021-11-01 20:30 ET
Mirati Therapeutics to Report Financial Results for Third Quarter 2021 and Recent Corporate Updates on November 8, 2021
2021-10-07 20:30 ET
Mirati Therapeutics to Collaborate with Sanofi on Phase 1/2 Study Evaluating Combination of adagrasib with a SHP2 Inhibitor in KRAS G12C-mutated Lung Cancer
2021-10-04 20:30 ET
Mirati Therapeutics to Present New Research From its Innovative Oncology Pipeline at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer
2021-09-24 20:15 ET
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2021-09-20 12:20 ET
Mirati Therapeutics Announces Long-term Survival Results from an Exploratory Analysis of Sitravatinib plus Nivolumab in Patients with Non-squamous Non-Small Cell Lung Cancer Who are Resistant to Checkpoint Inhibitors
2021-09-20 11:55 ET
Mirati Therapeutics Appoints David Meek as Chief Executive Officer
2021-09-20 11:30 ET
Mirati Therapeutics Announces Positive Phase 2 Topline Results for Investigational Adagrasib in Patients with KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
2021-09-19 13:47 ET
Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib as Monotherapy and in Combination with Cetuximab in Patients with KRAS G12C-Mutated Colorectal Cancer
2021-09-15 20:15 ET
Mirati Therapeutics to Host Virtual Investor Event on Monday, September 20, 2021
2021-08-25 20:30 ET
Mirati Therapeutics Clinical Research at ESMO Congress 2021 to Highlight Progress with Investigational Adagrasib and Sitravatinib in Patients with Lung and Colorectal Cancers
2021-08-05 20:15 ET
Mirati Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Updates
2021-06-24 20:42 ET
Mirati Therapeutics' Adagrasib Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Patients with Advanced Non-Small Cell Lung Cancer Harboring the KRAS G12C Mutation
2021-06-02 20:15 ET
Mirati Therapeutics to Take Part in the 42nd Annual Goldman Sachs Global Healthcare Conference
2021-06-01 11:30 ET
Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China
2021-06-01 11:30 ET
Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China
2021-05-25 20:05 ET
QIAGEN Partners With Mirati Therapeutics Inc. to Develop KRASG12C Companion Diagnostic for Non-Small Cell Lung Cancer (NSCLC)
2021-05-06 20:15 ET
Mirati Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Updates
2021-04-19 13:00 ET
Stand Up To Cancer Announces $4 Million Grant From Mirati Therapeutics To Support Research On KRAS Mutant Cancers
2021-04-10 18:35 ET
Mirati Therapeutics Presents Preclinical Data on Novel Approach to PRMT5 Inhibition that Selectively Targets the PRMT5/MTA Complex in MTAP-Deleted Cancer Models
2021-03-31 11:30 ET
Mirati Therapeutics Board Elects Shalini Sharp as New Independent Director
2021-03-10 21:39 ET
Mirati Therapeutics to Present Late-Breaking Data That Advance the Understanding of Synthetic Lethal PRMT5 Inhibitors in MTAP-Deleted Cancers at AACR 2021
2021-02-25 21:15 ET
Mirati Therapeutics Reports Fourth Quarter And Full-Year 2020 Financial Results And Recent Corporate Updates
2021-02-18 21:15 ET
Mirati Therapeutics To Present At Upcoming Healthcare Conferences
2021-02-10 12:00 ET
MD Anderson And Mirati Therapeutics Announce KRAS Strategic Research And Development Collaboration In Solid Tumors
2021-02-04 21:30 ET
Mirati Therapeutics To Present At Guggenheim Healthcare Talks 2021 Oncology Days
2021-01-11 13:05 ET
Resolution Bioscience Announces Companion Diagnostic Collaboration with Mirati Therapeutics
2021-01-04 22:19 ET
Mirati Therapeutics To Present At The 39th Annual J.P. Morgan Healthcare Conference
2020-11-23 21:30 ET
Mirati Therapeutics To Participate In The 2020 Evercore ISI HealthCONx Conference
2020-11-05 21:30 ET
Mirati Therapeutics To Participate In The 29th Annual Credit Suisse Virtual Healthcare Conference
2020-11-04 21:15 ET
Mirati Therapeutics Reports Third Quarter 2020 Financial Results And Recent Business Highlights
2020-10-30 21:09 ET
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
2020-10-28 00:04 ET
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
2020-10-26 20:46 ET
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
2020-10-25 14:45 ET
Mirati Therapeutics Reports Investigational Adagrasib (MRTX849) Preliminary Data Demonstrating Tolerability and Durable Anti-Tumor Activity as well as Initial MRTX1133 Preclinical Data
2020-10-15 20:30 ET
Mirati Therapeutics To Present Data During The 2020 EORTC-NCI-AACR International Virtual Conference On Molecular Targets And Therapeutics (ENA)
2020-09-18 12:00 ET
Mirati Therapeutics Presents Phase 2 Data On Sitravatinib In Combination With Nivolumab In Urothelial Cancer At ESMO Virtual Congress
2020-09-17 12:01 ET
Boehringer Ingelheim And Mirati Therapeutics Announce Clinical Collaboration To Study BI 1701963, A SOS1::pan-KRAS Inhibitor In Combination With MRTX849, A KRAS G12C Selective Inhibitor
2020-09-17 12:00 ET
BOEHRINGER INGELHEIM AND MIRATI THERAPEUTICS ANNOUNCE CLINICAL COLLABORATION TO STUDY BI 1701963, A SOS1::PAN-KRAS INHIBITOR IN COMBINATION WITH MRTX849, A KRAS G12C SELECTIVE INHIBITOR
2020-09-03 20:30 ET
Mirati Therapeutics To Participate In Citi's 15th Annual Biopharma Virtual Conference
2020-08-13 12:03 ET
Strata Oncology Announces Partnership to Broaden Enrollment in Mirati Therapeutics' Clinical Trial of MRTX849, a Novel KRAS G12C Selective Inhibitor
2020-08-06 20:15 ET
Mirati Therapeutics Reports Second Quarter 2020 Financial Results And Recent Business Highlights
2020-08-05 20:05 ET
ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics
2020-06-05 13:00 ET
Mirati Therapeutics to Present at 41st Annual Goldman Sachs Global Healthcare Conference
2020-05-18 20:15 ET
Mirati Therapeutics Appoints Joseph A. Leveque, M.D. As Chief Medical Officer
2020-05-15 13:00 ET
Mirati Therapeutics To Present Preclinical Data From Investigational Pipeline Of Novel Therapeutics At 2020 American Association For Cancer Research Virtual Annual Meeting II
2020-05-07 20:05 ET
Mirati Therapeutics Reports First Quarter 2020 Financial Results And Recent Corporate Updates
2020-02-25 13:00 ET
Mirati Therapeutics Reports Year-End 2019 Financial Results And Recent Corporate Updates
2020-02-19 13:30 ET
Mirati Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-02-15 16:30 ET
Mirati Therapeutics Announces Initial Data In Renal Cell Carcinoma From Ongoing Investigator Sponsored Clinical Trial Of Sitravatinib In Combination With Nivolumab At The 2020 ASCO Genitourinary Cancers Syposium
2020-01-14 21:01 ET
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
2020-01-10 03:00 ET
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
2020-01-08 21:04 ET
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
2020-01-06 21:30 ET
Mirati Therapeutics Announces Executive Management Changes
2020-01-02 21:30 ET
Mirati Therapeutics To Present At The 38th Annual J.P. Morgan Healthcare Conference
2019-11-04 21:15 ET
Mirati Therapeutics Reports Third Quarter 2019 Financial Results
2019-10-28 20:15 ET
Mirati Therapeutics Presents First Clinical Data Of Phase 1/2 Trial Of MRTX849 At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
2019-10-23 20:45 ET
Mirati Therapeutics Announces Presentation Of Interim Phase 2 Sitravatinib Data In Urothelial Carcinoma And Oral Cavity Squamous Cell Carcinoma At The SITC 34th Annual Meeting
2019-10-17 13:00 ET
Mirati Therapeutics To Present Pre-Clinical And Initial Clinical Data For MRTX849, A KRAS G12C Inhibitor, At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
2019-08-15 20:30 ET
Mirati Therapeutics Appoints Jenny Gizzi As Vice President, Human Resources
2019-08-05 20:15 ET
Mirati Therapeutics Reports Second Quarter 2019 Financial Results
2019-07-09 20:30 ET
Mirati Announces Clinical Collaboration to Evaluate MRTX849 in Combination with SHP2 Inhibitor TNO155
2019-07-01 20:30 ET
Mirati Therapeutics Announces The Appointment Of Dr. Julie Cherrington To The Board Of Directors
2019-06-25 12:30 ET
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
2019-05-30 20:30 ET
Mirati Therapeutics To Present At Jefferies 2019 Global Healthcare Conference
2019-04-29 20:05 ET
Mirati Therapeutics Reports First Quarter 2019 Financial Results
2019-04-01 20:30 ET
Mirati Therapeutics To Present At The H.C. Wainwright & Co. Global Life Sciences Conference
2019-01-07 13:30 ET
Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®)

SEC forms

Show financial reports only

SEC form 8
2023-11-06 08:05 ET
Mirati Therapeutics reported for 2023 q3
SEC form 10
2023-11-06 07:08 ET
Mirati Therapeutics reported for 2023 q3
SEC form 10
2023-11-06 00:00 ET
Mirati Therapeutics reported for 2023 q3
SEC form 6
2023-08-09 16:40 ET
Mirati Therapeutics published news for 2023 q2
SEC form 10
2023-08-08 16:02 ET
Mirati Therapeutics reported for 2023 q2
SEC form 6
2023-08-08 16:01 ET
Mirati Therapeutics reported for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Mirati Therapeutics reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Mirati Therapeutics reported for 2023 q2
SEC form 6
2023-07-21 06:05 ET
Mirati Therapeutics published news for 2023 q2
SEC form 6
2023-06-23 17:16 ET
Mirati Therapeutics published news for 2023 q1
SEC form 6
2023-06-23 16:02 ET
Mirati Therapeutics published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Mirati Therapeutics reported for 2023 q1
SEC form 10
2023-05-09 00:00 ET
Mirati Therapeutics reported for 2023 q1
SEC form 10
2023-02-28 16:26 ET
Mirati Therapeutics reported for 2022 q4
SEC form 6
2023-02-28 16:08 ET
Mirati Therapeutics reported for 2022 q4
SEC form 10
2023-02-28 00:00 ET
Mirati Therapeutics reported for 2022 q4
SEC form 8
2023-02-28 00:00 ET
Mirati Therapeutics reported for 2022 q4
SEC form 6
2023-01-24 16:20 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2023-01-24 16:19 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2023-01-24 16:17 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2023-01-24 16:03 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2023-01-24 16:00 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2023-01-24 16:00 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2023-01-24 16:00 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2023-01-24 16:00 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2023-01-20 09:20 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2023-01-09 13:06 ET
Mirati Therapeutics published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2022-12-21 21:20 ET
Mirati Therapeutics published news for 2022 q3
SEC form 6
2022-12-21 21:20 ET
Mirati Therapeutics published news for 2022 q3
SEC form 6
2022-12-12 20:22 ET
Mirati Therapeutics published news for 2022 q3
SEC form 6
2022-12-05 19:00 ET
Mirati Therapeutics published news for 2022 q3
SEC form 6
2022-12-05 17:00 ET
Mirati Therapeutics published news for 2022 q3
SEC form 6
2022-12-02 08:01 ET
Mirati Therapeutics published news for 2022 q3
SEC form 6
2022-11-28 19:01 ET
Mirati Therapeutics published news for 2022 q3
SEC form 6
2022-11-08 18:00 ET
Mirati Therapeutics published news for 2022 q3
SEC form 10
2022-11-08 16:32 ET
Mirati Therapeutics reported for 2022 q3
SEC form 6
2022-11-08 16:23 ET
Mirati Therapeutics published news for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Mirati Therapeutics reported for 2022 q3
SEC form 10
2022-11-08 00:00 ET
Mirati Therapeutics reported for 2022 q3
SEC form 6
2022-09-08 06:08 ET
Mirati Therapeutics published news for 2022 q2
SEC form 10
2022-08-03 16:07 ET
Mirati Therapeutics reported for 2022 q2
SEC form 6
2022-08-03 16:04 ET
Mirati Therapeutics published news for 2022 q2
SEC form 8
2022-08-03 00:00 ET
Mirati Therapeutics reported for 2022 q2
SEC form 10
2022-08-03 00:00 ET
Mirati Therapeutics reported for 2022 q2
SEC form 6
2022-06-14 16:35 ET
Mirati Therapeutics published news for 2022 q1
SEC form 6
2022-06-07 08:06 ET
Mirati Therapeutics published news for 2022 q1
SEC form 6
2022-06-06 08:07 ET
Mirati Therapeutics published news for 2022 q1
SEC form 6
2022-05-26 17:06 ET
Mirati Therapeutics published news for 2022 q1
SEC form 6
2022-05-16 17:01 ET
Mirati Therapeutics published news for 2022 q1
SEC form 6
2022-05-16 16:42 ET
Mirati Therapeutics published news for 2022 q1
SEC form 6
2022-05-12 17:07 ET
Mirati Therapeutics published news for 2022 q1
SEC form 10
2022-05-04 16:22 ET
Mirati Therapeutics reported for 2022 q1
SEC form 6
2022-05-04 16:10 ET
Mirati Therapeutics reported for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Mirati Therapeutics reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Mirati Therapeutics reported for 2022 q1
SEC form 6
2022-04-15 16:26 ET
Mirati Therapeutics published news for 2022 q1
SEC form 10
2022-02-28 16:20 ET
Mirati Therapeutics published news for 2021 q4
SEC form 6
2022-02-28 16:06 ET
Mirati Therapeutics published news for 2021 q4
SEC form 10
2022-02-28 00:00 ET
Mirati Therapeutics published news for 2021 q4
SEC form 8
2022-02-28 00:00 ET
Mirati Therapeutics published news for 2021 q4
SEC form 6
2022-02-15 16:16 ET
Mirati Therapeutics published news for 2021 q4
SEC form 6
2022-01-10 10:55 ET
Mirati Therapeutics published news for 2021 q4
SEC form 6
2021-11-12 06:16 ET
Mirati Therapeutics published news for 2021 q3
SEC form 6
2021-11-09 16:24 ET
Mirati Therapeutics published news for 2021 q3
SEC form 10
2021-11-08 16:25 ET
Mirati Therapeutics published news for 2021 q3
SEC form 6
2021-11-08 16:08 ET
Mirati Therapeutics published news for 2021 q3
SEC form 8
2021-11-08 00:00 ET
Mirati Therapeutics published news for 2021 q3
SEC form 10
2021-11-08 00:00 ET
Mirati Therapeutics published news for 2021 q3
SEC form 6
2021-11-01 07:32 ET
Mirati Therapeutics published news for 2021 q3
SEC form 6
2021-09-24 17:10 ET
Mirati Therapeutics published news for 2021 q2
SEC form 6
2021-09-20 08:10 ET
Mirati Therapeutics published news for 2021 q2
SEC form 10
2021-08-05 16:42 ET
Mirati Therapeutics published news for 2021 q2
SEC form 6
2021-08-05 16:34 ET
Mirati Therapeutics published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Mirati Therapeutics published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Mirati Therapeutics published news for 2021 q2
SEC form 6
2021-07-02 16:04 ET
Mirati Therapeutics published news for 2021 q2
SEC form 6
2021-06-28 17:02 ET
Mirati Therapeutics published news for 2021 q1
SEC form 6
2021-06-01 08:41 ET
Mirati Therapeutics published news for 2021 q1
SEC form 6
2021-05-12 16:21 ET
Mirati Therapeutics published news for 2021 q1
SEC form 10
2021-05-06 16:37 ET
Mirati Therapeutics published news for 2021 q1
SEC form 6
2021-05-06 16:28 ET
Mirati Therapeutics published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Mirati Therapeutics published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Mirati Therapeutics published news for 2021 q1
SEC form 6
2021-04-16 16:26 ET
Mirati Therapeutics published news for 2021 q1
SEC form 6
2021-03-30 17:41 ET
Mirati Therapeutics published news for 2020 q4
SEC form 6
2021-03-30 17:09 ET
Mirati Therapeutics published news for 2020 q4
SEC form 10
2021-02-25 16:37 ET
Mirati Therapeutics published news for 2020 q4
SEC form 6
2021-02-25 16:31 ET
Mirati Therapeutics published news for 2020 q4
SEC form 6
2021-01-11 07:31 ET
Mirati Therapeutics published news for 2020 q4
SEC form 6
2021-01-08 19:57 ET
Mirati Therapeutics published news for 2020 q4
SEC form 10
2020-11-04 16:47 ET
Mirati Therapeutics published news for 2020 q3
SEC form 6
2020-11-04 16:36 ET
Mirati Therapeutics published news for 2020 q3
SEC form 6
2020-10-28 16:38 ET
Mirati Therapeutics published news for 2020 q3
SEC form 6
2020-10-26 16:53 ET
Mirati Therapeutics published news for 2020 q3
SEC form 6
2020-10-26 08:00 ET
Mirati Therapeutics published news for 2020 q3